Randomised controlled trial of mesalazine in IBS

Giovanni Barbara, Cesare Cremon, Vito Annese, Guido Basilisco, Franco Bazzoli, Massimo Bellini, Antonio Benedetti, Luigi Benini, Fabrizio Bossa, Paola Buldrini, Michele Cicala, Rosario Cuomo, Bastianello Germanà, Paola Molteni, Matteo Neri, Marcello Rodi, Alfredo Saggioro, Maria Lia Scribano, Maurizio Vecchi, Giorgio Zoli, Roberto Corinaldesi, Vincenzo Stanghellini, Giovanni Barbara, Cesare Cremon, Vito Annese, Guido Basilisco, Franco Bazzoli, Massimo Bellini, Antonio Benedetti, Luigi Benini, Fabrizio Bossa, Paola Buldrini, Michele Cicala, Rosario Cuomo, Bastianello Germanà, Paola Molteni, Matteo Neri, Marcello Rodi, Alfredo Saggioro, Maria Lia Scribano, Maurizio Vecchi, Giorgio Zoli, Roberto Corinaldesi, Vincenzo Stanghellini

Abstract

Objective: Low-grade intestinal inflammation plays a role in the pathophysiology of IBS. In this trial, we aimed at evaluating the efficacy and safety of mesalazine in patients with IBS.

Design: We conducted a phase 3, multicentre, tertiary setting, randomised, double-blind, placebo-controlled trial in patients with Rome III confirmed IBS. Patients were randomly assigned to either mesalazine, 800 mg, or placebo, three times daily for 12 weeks, and were followed for additional 12 weeks. The primary efficacy endpoint was satisfactory relief of abdominal pain/discomfort for at least half of the weeks of the treatment period. The key secondary endpoint was satisfactory relief of overall IBS symptoms. Supportive analyses were also performed classifying as responders patients with a percentage of affirmative answers of at least 75% or >75% of time.

Results: A total of 185 patients with IBS were enrolled from 21 centres. For the primary endpoint, the responder patients were 68.6% in the mesalazine group versus 67.4% in the placebo group (p=0.870; 95% CI -12.8 to 15.1). In explorative analyses, with the 75% rule or >75% rule, the percentage of responders was greater in the mesalazine group with a difference over placebo of 11.6% (p=0.115; 95% CI -2.7% to 26.0%) and 5.9% (p=0.404; 95% CI -7.8% to 19.4%), respectively, although these differences were not significant. For the key secondary endpoint, overall symptoms improved in the mesalazine group and reached a significant difference of 15.1% versus placebo (p=0.032; 95% CI 1.5% to 28.7%) with the >75% rule.

Conclusions: Mesalazine treatment was not superior than placebo on the study primary endpoint. However, a subgroup of patients with IBS showed a sustained therapy response and benefits from a mesalazine therapy.

Trial registration number: ClincialTrials.gov number, NCT00626288.

Keywords: ABDOMINAL PAIN; CLINICAL TRIALS; GUT INFLAMMATION; INFLAMMATORY CELLS; IRRITABLE BOWEL SYNDROME.

Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/

Figures

Figure 1
Figure 1
Study design. There was a screening period of 2 weeks before randomisation (1:1), a 12-week placebo-controlled treatment period and a 12-week follow-up period. Study visits occurred every two weeks during treatment period and every four weeks during follow-up.
Figure 2
Figure 2
Flow chart of enrolment and randomisation of the study. A total of 185 patients with IBS were included in the study. Of these, five were not randomised and were excluded from all analyses. Of the 180 patients randomised, 88 were allocated to mesalazine and 92 to placebo. One patient randomised to placebo did not take at least one dose of the study treatment. Seven other patients were excluded from the intention-to-treat (ITT) population as they did not have any evaluation of the primary endpoint. Thus, 172 subjects were included in the ITT population. PP, per protocol.
Figure 3
Figure 3
Primary efficacy analysis (satisfactory relief of abdominal pain or discomfort). The logistic model for repeated measures did not reveal a statistically significant effect for treatment (p=0.324) nor interaction between treatment and time (p=0.897). The answers varied significantly with time (pExplorative analyses. With the 75% rule, 43.0% of patients in the mesalazine group were responders versus 31.4% in the placebo group, with a δ difference of 11.6% (p=0.115; 95% CI −2.7% to 26.0%) (B). With the >75% rule, 32.6% of responder patients were identified in the mesalazine group versus 26.7% of patients in the placebo group, with a δ difference of 5.9% (p=0.404; 95% CI −7.8% to 19.4%) (B).
Figure 4
Figure 4
Secondary efficacy analysis (satisfactory relief of the overall IBS symptoms). The logistic model for repeated measures did not reveal statistically significant effect for treatment (p=0.155) nor interaction between treatment and time (p=0.640). The answers varied significantly with time (p=0.004). Using the same model to test the simple main effect, a borderline significant effect was detected at week 3 (p=0.060) and a statistical significance was detected at week 5 (p=0.038) (A). According to the prevalence approach, responder patients were 66.3% in the mesalazine group versus 61.6% in the placebo group, with a δ in favour of the mesalazine group of 4.7% (p=0.525; 95% CI −9.7% to 19.0%) (B). Explorative analyses. With the 75% rule, 46.5% of patients in the mesalazine group were responders versus 34.9% in the placebo group, with a δ difference of 11.6% (p=0.121; 95% CI −3.0% to 26.2%) (B). With the >75% rule, 38.4% of responder patients were identified in the mesalazine group versus 23.3% of patients in the placebo group, with a δ difference of 15.4% (p=0.032; 95% CI 1.5% to 28.7%) (B).

References

    1. Longstreth GF, Thompson WG, Chey WD, et al. . Functional bowel disorders. Gastroenterology 2006;130:1480–91.
    1. Camilleri M. Peripheral mechanisms in irritable bowel syndrome. N Engl J Med 2013;368:578–9.
    1. Barbara G, Cremon C, Carini G, et al. . The immune system in irritable bowel syndrome. J Neurogastroenterol Motil 2011;17:349–59.
    1. Spiller R, Garsed K. Postinfectious irritable bowel syndrome. Gastroenterology 2009;136:1979–88.
    1. Cremon C, Stanghellini V, Pallotti F, et al. . Salmonella gastroenteritis during childhood is a risk factor for irritable bowel syndrome in adulthood. Gastroenterology 2014;147:69–77.
    1. Piche T, Barbara G, Aubert P, et al. . Impaired intestinal barrier integrity in the colon of patients with irritable bowel syndrome: involvement of soluble mediators. Gut 2009;58:196–201.
    1. Cremon C, Carini G, Wang B, et al. . Intestinal serotonin release, sensory neuron activation, and abdominal pain in irritable bowel syndrome. Am J Gastroenterol 2011;106:1290–8.
    1. Foley S, Garsed K, Singh G, et al. . Impaired uptake of serotonin by platelets from patients with irritable bowel syndrome correlates with duodenal immune activation. Gastroenterology 2011;140:1434–43 e1.
    1. Barbara G, Wang B, Stanghellini V, et al. . Mast cell-dependent excitation of visceral-nociceptive sensory neurons in irritable bowel syndrome. Gastroenterology 2007;132:26–37.
    1. Cenac N, Andrews CN, Holzhausen M, et al. . Role for protease activity in visceral pain in irritable bowel syndrome. J Clin Invest 2007;117:636–47.
    1. Buhner S, Li Q, Berger T, et al. . Submucous rather than myenteric neurons are activated by mucosal biopsy supernatants from irritable bowel syndrome patients. Neurogastroenterol Motil 2012;24:1134–e572.
    1. Buhner S, Li Q, Vignali S, et al. . Activation of human enteric neurons by supernatants of colonic biopsy specimens from patients with irritable bowel syndrome. Gastroenterology 2009;137:1425–34.
    1. Balestra B, Vicini R, Cremon C, et al. . Colonic mucosal mediators from patients with irritable bowel syndrome excite enteric cholinergic motor neurons. Neurogastroenterol Motil 2012;24:1118–e570.
    1. Zucchelli M, Camilleri M, Andreasson AN, et al. . Association of TNFSF15 polymorphism with irritable bowel syndrome. Gut 2011;60:1671–7.
    1. Swan C, Duroudier NP, Campbell E, et al. . Identifying and testing candidate genetic polymorphisms in the irritable bowel syndrome (IBS): association with TNFSF15 and TNFalpha. Gut 2013;62:985–94.
    1. Piche T, Saint-Paul MC, Dainese R, et al. . Mast cells and cellularity of the colonic mucosa correlated with fatigue and depression in irritable bowel syndrome. Gut 2008;57:468–73.
    1. Vivinus-Nebot M, Dainese R, Anty R, et al. . Combination of allergic factors can worsen diarrheic irritable bowel syndrome: role of barrier defects and mast cells. Am J Gastroenterol 2012;107:75–81.
    1. Simren M, Barbara G, Flint HJ, et al. . Intestinal microbiota in functional bowel disorders: a Rome foundation report. Gut 2013;62:159–76.
    1. Corinaldesi R, Stanghellini V, Cremon C, et al. . Effect of mesalazine on mucosal immune biomarkers in irritable bowel syndrome: a randomized controlled proof-of-concept study. Aliment Pharmacol Ther 2009;30:245–52.
    1. Dunlop SP, Jenkins D, Neal KR, et al. . Randomized, double-blind, placebo-controlled trial of prednisolone in post-infectious irritable bowel syndrome. Aliment Pharmacol Ther 2003;18:77–84.
    1. Barbara G, Stanghellini V, Cremon C, et al. . Aminosalicylates and other anti-inflammatory compounds for irritable bowel syndrome. Dig Dis 2009;27(Suppl 1):115–21.
    1. Klooker TK, Braak B, Koopman KE, et al. . The mast cell stabiliser ketotifen decreases visceral hypersensitivity and improves intestinal symptoms in patients with irritable bowel syndrome. Gut 2010;59:1213–21.
    1. Mowat C, Cole A, Windsor A, et al. . Guidelines for the management of inflammatory bowel disease in adults. Gut 2011;60:571–607.
    1. Patrick DL, Drossman DA, Frederick IO, et al. . Quality of life in persons with irritable bowel syndrome: development and validation of a new measure. Dig Dis Sci 1998;43:400–11.
    1. Ware JE Jr, Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care 1992;30:473–83.
    1. Irvine EJ, Whitehead WE, Chey WD, et al. . Design of treatment trials for functional gastrointestinal disorders. Gastroenterology 2006;130:1538–51.
    1. Camilleri M, Northcutt AR, Kong S, et al. . Efficacy and safety of alosetron in women with irritable bowel syndrome: a randomised, placebo-controlled trial. Lancet 2000;355:1035–40.
    1. Tack J, Muller-Lissner S, Bytzer P, et al. . A randomised controlled trial assessing the efficacy and safety of repeated tegaserod therapy in women with irritable bowel syndrome with constipation. Gut 2005;54:1707–13.
    1. Muller-Lissner SA, Fumagalli I, Bardhan KD, et al. . Tegaserod, a 5-HT(4) receptor partial agonist, relieves symptoms in irritable bowel syndrome patients with abdominal pain, bloating and constipation. Aliment Pharmacol Ther 2001;15:1655–66.
    1. Lembo A, Ameen VZ, Drossman DA. Irritable bowel syndrome: toward an understanding of severity. Clin Gastroenterol Hepatol 2005;3:717–25.
    1. Spiegel B, Bolus R, Harris LA, et al. . Measuring irritable bowel syndrome patient-reported outcomes with an abdominal pain numeric rating scale. Aliment Pharmacol Ther 2009;30:1159–70.
    1. Corsetti M, Tack J. FDA and EMA end points: which outcome end points should we use in clinical trials in patients with irritable bowel syndrome? Neurogastroenterol Motil 2013;25:453–7.
    1. Cremon C, Gargano L, Morselli-Labate AM, et al. . Mucosal immune activation in irritable bowel syndrome: gender-dependence and association with digestive symptoms. Am J Gastroenterol 2009;104:392–400.
    1. Enck P, Bingel U, Schedlowski M, et al. . The placebo response in medicine: minimize, maximize or personalize? Nat Rev Drug Discov 2013;12:191–204.
    1. Lembo AJ, Schneier HA, Shiff SJ, et al. . Two randomized trials of linaclotide for chronic constipation. N Engl J Med 2011;365:527–36.
    1. Barbara G, Stanghellini V, De Giorgio R, et al. . Activated mast cells in proximity to colonic nerves correlate with abdominal pain in irritable bowel syndrome. Gastroenterology 2004;126:693–702.
    1. Feagan BG, Macdonald JK. Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis. Cochrane Database Syst Rev 2012;10:CD000544.

Source: PubMed

Спонсоры и соавторы

Заболевания

Медикаментозные вмешательства

Подписаться